宫颈癌近距离放疗使用率下降趋势是否已逆转?
该研究基于美国国家癌症数据库(NCDB)2004至2014年接受根治性放化疗的FIGO IIB-IVA期宫颈癌患者共17,442例,分析近距离放疗使用率随时间及保险类型的变化。结果显示2008-10年使用率下降,政府保险患者下降更显著,但2011-14年所有保险组均回升,医疗补助和无保险患者改善尤为明显。
要点
- 2008-10年近距离放疗使用率较2004-07年下降,政府保险患者下降更显著。
- 2011-14年所有保险组使用率回升,医疗补助和无保险患者改善明显。
- 建议替代支付模式应激励宫颈近距离放疗以巩固使用率增益。
核心结论
- 2004-2014年间FIGO IIB-IVA期宫颈癌根治性放化疗患者中,近距离放疗使用率在2000年代后期下降且对政府保险患者影响更大,但2010年代初期已回升。
研究设计与样本
- 回顾性队列研究,查询美国国家癌症数据库(NCDB),纳入2004至2014年接受根治性放化疗的FIGO IIB-IVA期宫颈癌患者17,442例。
- 采用二元逻辑回归比较不同保险类型及社会人口学因素下近距离放疗使用率随时间的变化,并在子队列中使用boost modality变量进行敏感性分析。
主要发现
- 2008-10年近距离放疗使用率为52.6%,2004-07年为54.4%(OR 0.93,95%CI 0.86-1.01)。
- 政府保险患者使用率从52.3%降至49.4%,私营保险患者从58.9%降至57.6%。
- 2011-14年所有保险组使用率回升至58.0%(OR 1.24,95%CI 1.16-1.34),医疗补助(OR 1.44,95%CI 1.26-1.65)和无保险患者(OR 1.28,95%CI 1.03-1.57)改善更明显。
- 敏感性分析使用boost modality变量确认了上述趋势。
临床怎么用
- 临床应关注政府保险等脆弱人群的近距离放疗可及性,避免使用率再次下降。
- 政策制定者可考虑在替代支付模型中激励宫颈近距离放疗,以巩固使用率增益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Studies examining temporal trends in cervical brachytherapy use are conflicting and examined different health insurance populations. This study examined brachytherapy utilization over time by health insurance type and whether reported declines in brachytherapy have reversed. METHODS: The National Cancer Database (NCDB) was queried for patients with FIGO IIB-IVA cervical cancer treated with definitive chemoradiotherapy between 2004 and 2014, identifying 17,442 patients. Brachytherapy utilization over time and by insurance type and other sociodemographic factors were compared using binary logistic regression. A sensitivity analysis was done in a sub-cohort of patients using the boost modality variable in the NCDB. RESULTS: Brachytherapy utilization declined during 2008-10 (52.6%) compared to 2004-2007 (54.4%; odds ratio [OR] 0.93, 95% confidence interval [CI] 0.86-1.01) and declines were disproportionately larger for patients with government insurance (49.4% vs 52.3%, respectively) than privately-insured patients (57.6% vs 58.9%, respectively). However, rates of brachytherapy use subsequently recovered during 2011-14 in all insurance groups (58.0%, OR 1.24, 95% CI 1.16-1.34) and was especially improved for Medicaid (OR 1.44, 95% CI 1.26-1.65) and uninsured patients (OR 1.28, 95% CI 1.03-1.57). Sensitivity analysis using the boost modality variable confirmed these trends. CONCLUSIONS: In patients with FIGO IIB-IVA cervical cancer treated with definitive chemoradiotherapy from 2004 to 2014, brachytherapy utilization declined during the late 2000s and disproportionately affected patients with government insurance, but subsequently recovered in the early 2010s. Since government insurance covers vulnerable patient populations at-risk for future declines in brachytherapy use, proposed alternative payment models should incentivize cervical brachytherapy to solidify gains in brachytherapy utilization.
引用
- Schad MD, Patel AK, Glaser SM, et al. Declining brachytherapy utilization for cervical cancer patients - Have we reversed the trend? Gynecol Oncol. 2020. PMID: 31924333. doi:10.1016/j.ygyno.2019.12.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。